Sagar Lonial
Emory University Winship Cancer Institute · Winship Cancer Institute, Emory University · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sagar Lonial as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:09 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT01485835 · A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple MyelomaEmory University · completed · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT01323751 · Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple MyelomaCelgene · completed · Multiple Myeloma · principal investigator
- Ph3NCT01169337 · Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple MyelomaNational Cancer Institute (NCI) · active not recruiting · Light Chain Deposition Disease, Smoldering Multiple Myeloma · principal investigator
- Ph1NCT00972712 · Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple MyelomaEmory University · completed · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT00793650 · Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding StudyEmory University · terminated · Cancer, Multiple Myeloma · principal investigator
- Ph1NCT00547404 · Phase I Study for Safety and Efficacy of P276-00 in Subjects With MyelomaPiramal Enterprises Limited · withdrawn · Multiple Myeloma · principal investigator
- Ph2NCT00208949 · A Comparison of Dendritic Cell Content and T-Cell Phenotype Between Granulocyte Colony-Stimulating Factor (G-CSF) or G-CSF + Granulocyte Macrophage (GM)-CSFEmory University · terminated · Hematologic Diseases · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- PHARMACOKINETICS AND PHARMACODYNAMICS OF BORTEZOMIB IN MULTIPLE MYELOMAM01RR000039 · NCRR · EMORY UNIVERSITY · fiscal years 2005 to 2006 · $9,669 awarded in 2006Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Eastern Cooperative Oncology Group Operations OfficeU10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 1985 to 2013Named on NCT01169337
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT01169337
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2015 to 2026Named on NCT01169337
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 11:09 UTC. The ranking covers the 200 most relevant of 96 PubMed records, and a shared surname and initials can bring in a namesake. All 96 on PubMed
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 20212,208 citationsRCR 120.1
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.N Engl J Med · 20052,076 citationsRCR 41.6
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.N Engl J Med · 20151,116 citationsRCR 34.1
- 1,038 citationsRCR 22.6
- 730 citationsRCR 17.8
- 715 citationsRCR 23.2
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.Lancet Oncol · 2020666 citationsRCR 30.2
- 659 citationsRCR 17.6
- Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.J Clin Oncol · 2006610 citationsRCR 12.2
- Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.N Engl J Med · 2019550 citationsRCR 19.6